- ISIN
- US04351P1012
- CUSIP
- 04351P101
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jan 28, 2015
Highlights
- Market Cap
- $15.15B
- Enterprise Value
- $16.11B
- EPS (TTM)
- €8.13
- PE Ratio
- 26.01
- PEG Ratio
- 0.12
- Total Revenue (TTM)
- €867.51M
- Gross Profit (TTM)
- €764.89M
- EBITDA (TTM)
- -€6.94M
- Year Range
- $173.33 - $282.15
- Target Price
- $286.83
- ROA (TTM)
- 25.26%
- ROE (TTM)
- 103.71%
- Avg. Volume (1M)
- 516K
- Avg. Volume Value (1M)
- $134.94M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ASND Performance Chart
Ascendis Pharma A/S (ASND) is up 14.4% since the beginning of the year. At $244 per share, ASND is trading 13.6% below its 52-week high of $282. Investors who bought $1,000 worth of ASND shares 5 years ago would now be looking at an investment worth $2,063.
Loading charts...
Compare this symbol against anything
Returns By Period
Ascendis Pharma A/S (ASND) has returned 14.38% so far this year and 39.79% over the past 12 months. Looking at the last ten years, ASND has achieved an annualized return of 33.00%, outperforming the S&P 500 Index benchmark, which averaged 13.26% per year.
Ascendis Pharma A/S
- 1D
- -2.85%
- 1M
- -11.14%
- 6M
- 7.88%
- YTD
- 14.38%
- 1Y
- 39.79%
- 3Y*
- 38.59%
- 5Y*
- 15.59%
- 10Y*
- 33.00%
- ALL TIME*
- 23.51%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
ASND Monthly Returns History
Based on dividend-adjusted daily data since Jan 28, 2015, ASND's average daily return is +0.13%, while the average monthly return is +2.44%. At this rate, an investment would double in approximately 2.4 years.
Historically, 56% of months were positive and 44% were negative. The best month was Mar 2019 with a return of +61.6%, while the worst month was Apr 2023 at -34.8%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ASND closed higher 49% of trading days. The best single day was Mar 4, 2019 with a return of +74.0%, while the worst single day was Apr 3, 2023 at -32.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 6.03% | 3.27% | -2.04% | 0.28% | -2.30% | 19.01% | -8.55% | 14.38% | |||||
| 2025 | -5.09% | 19.84% | -0.46% | 9.35% | -4.46% | 5.99% | 0.52% | 11.97% | 2.34% | 1.40% | 5.32% | 0.43% | 54.89% |
| 2024 | 3.16% | 13.72% | 2.31% | -8.42% | -2.41% | 0.95% | -2.11% | 3.71% | 7.84% | -17.74% | 10.80% | 1.17% | 9.31% |
| 2023 | 1.60% | -10.47% | -3.48% | -34.75% | 24.31% | 2.62% | 1.01% | 8.73% | -4.47% | -4.62% | 12.45% | 25.41% | 3.13% |
| 2022 | -9.58% | -7.60% | 4.42% | -22.23% | -7.41% | 10.00% | -7.99% | 4.72% | 15.28% | 11.37% | 7.01% | -0.76% | -9.22% |
| 2021 | -9.97% | 3.21% | -16.84% | 12.48% | -7.30% | -2.11% | -10.16% | 32.61% | 1.70% | -4.88% | -9.62% | -1.82% | -19.34% |
Benchmark Metrics
Ascendis Pharma A/S has an annualized alpha of 27.51%, beta of 0.70, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since January 28, 2015.
- This stock participates in less of S&P 500 Index's moves in both directions, but captures a larger share of gains (86.95%) than losses (18.69%) - typical of diversified or defensive assets.
- Beta of 0.70 may look defensive, but with R2 of 0.06 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 27.51%
- Beta
- 0.70
- R²
- 0.06
- Upside Capture
- 86.95%
- Downside Capture
- 18.69%
Return for Risk
Risk / Return Rank
ASND ranks 78 for risk / return — above 78% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Ascendis Pharma A/S (ASND) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ASND | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.33 | ||
| Sortino ratioReturn per unit of downside risk | -0.26 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 1.25 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 2.35 | 2.00 | +0.34 |
| Martin ratioReturn relative to average drawdown | 6.86 | 8.49 | -1.63 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Ascendis Pharma A/S. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Ascendis Pharma A/S was 61.72%, occurring on Apr 28, 2023. Recovery took 567 trading sessions.
The current Ascendis Pharma A/S drawdown is 12.00%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-61.72%Apr 2023 | 2y 4mo | 2y 3mo | 4y 7moDec 2020 - Aug 2025 | — |
-43.02%Jun 2016 | 1y 4mo | 7mo 29d | 2y 5dJan 2015 - Feb 2017 | — |
-33.15%Mar 2020 | 24d | 2mo 5d | 2mo 29dFeb 2020 - May 2020 | COVID crash2020 |
-30.77%Oct 2019 | 4mo 7d | 2mo 18d | 6mo 25dJun 2019 - Dec 2019 | — |
-27.69%Dec 2018 | 3mo 28d | 2mo 10d | 6mo 8dAug 2018 - Mar 2019 | Rate-hike selloffLate 2018 |
Drawdown Indicators
| ASND | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -61.72% | -56.78% | -4.94% |
Max Drawdown (1Y)Largest decline over 1 year | -17.62% | -9.10% | -8.52% |
Max Drawdown (3Y)Largest decline over 3 years | -29.15% | -18.90% | -10.25% |
Max Drawdown (5Y)Largest decline over 5 years | -60.46% | -25.43% | -35.03% |
Max Drawdown (10Y)Largest decline over 10 years | -61.72% | -33.92% | -27.80% |
Current DrawdownCurrent decline from peak | -12.00% | -1.58% | -10.42% |
Average DrawdownAverage peak-to-trough decline | -18.75% | -10.70% | -8.05% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 5.98% | 2.14% | +3.84% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Ascendis Pharma A/S over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Ascendis Pharma A/S is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ASND, comparing it with other companies in the Biotechnology industry. Currently, ASND has a P/E ratio of 26.0. This P/E ratio is in line with the industry average, suggesting the stock may be fairly valued relative to its earnings.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ASND compared to other companies in the Biotechnology industry. ASND currently has a PEG ratio of 0.1. This PEG ratio is close to the industry average, suggesting the stock’s valuation is balanced against its growth outlook.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ASND relative to other companies in the Biotechnology industry. Currently, ASND has a P/S ratio of 15.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ASND in comparison with other companies in the Biotechnology industry. Currently, ASND has a P/B value of 27.9. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ASND
Add Ascendis Pharma A/S to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ASND